<DOC>
	<DOC>NCT00620425</DOC>
	<brief_summary>Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6 mg sumatriptan. Healthy Individuals will be enrolled for a series of 3 injections over 2 days. Assessment of Local Site Signs will be recorded for up to 5 days, as needed.</brief_summary>
	<brief_title>A Study on the Effects of Repeat Doses of IntrajectÂ® Sumatriptan on Local Site Signs</brief_title>
	<detailed_description>This study will evaluate the extent, persistence, and any cumulative effects on skin tissue by assessing local injection site reactions (bleeding, swelling, erythema, bruising) following repeated administrations of needle-free Intraject sumatriptan to the same anatomic site.</detailed_description>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Female subjects of childbearing potential must agree to use acceptable birth control Have abdominal or thigh injection sites that have sufficient subcutaneous tissue for needlefree injection Fluent in the spoken and written English language Provide written informed consent to participate in the study and be willing to comply with the study procedures Nontobacco user for at least 12 months prior to screening (all types of tobacco, including cigars) A history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes including ischemic or vasospastic coronary artery disease Other significant underlying cardiovascular diseases including uncontrolled hypertension Hemiplegic or basilar migraine A history or diagnosis of severe hepatic or renal impairment A history of epilepsy or seizure or other serious neurologic condition A history of allergy, anaphylaxis, or hypersensitivity to sumatriptan or any of its components or similar drugs A history of scleroderma (systemic sclerosis) or any skin condition that may adversely affect the injection or absorption of subcutaneously administered medications Tattoos, birthmarks or other significant skin discoloration in the thigh or abdominal area that are large enough to restrict injection site selection and/or evaluation Pregnancy or breastfeeding Have participated in a clinical trial or receipt of an experimental therapy within 30 days prior to dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>sumatriptan</keyword>
	<keyword>Intraject</keyword>
	<keyword>Local Site Reactions</keyword>
</DOC>